Astellas and the University of Tokyo Extend Partnership to Develop Novel Therapies

Astellas Pharma has entered the second phase of a collaboration with the University of Tokyo to jointly develop new therapies and medical solutions.

The partnership is called Astellas Alliance Acceleration Program (AAAP).

During the initial phase which lasted from September 2020 to March of this year, the AAAP established a foundation for the alliance at the university’s Institute for Life Sciences Research and Education and at the University of Tokyo Innovation Center.

Additionally, during this time, medical and pharmaceutical scientists from both academic organizations and drug discovery experts from Astellas created an environment conducive to discussions, which resulted in the identification and initiation of various new research projects. research.

As part of the latest second phase of the alliance, the university will expand its collaborative commitment to integrate all of its institutions.

In addition, to facilitate the alliance, a recently recruited dedicated AAAP project manager will be stationed at the institution.

This work will help the parties develop new research projects by merging the scientific research of the University of Tokyo with Astellas’ expertise in drug discovery.

Yoshitsugu Shitaka, Chief Scientific Officer of Astellas, said, “By leveraging the power of broader and closer collaboration, we plan to accelerate the co-creation of innovations that contribute to our business, from research early on from drug discovery to clinical development.

In December last year, Astellas entered into an option and license agreement with Dyno Therapeutics for the development of next-generation adeno-associated virus (AAV) gene therapy vectors for skeletal and cardiac muscle.

The gene therapy vectors were developed using Dyno’s CapsidMap platform, which uses artificial intelligence to rapidly optimize AAV capsids for delivery into various organs.

Related companies

About Margie Peters

Check Also

My day: Grainne Hughes, Almac Pharma Services

At 8am, I’m in my car and already halfway from the office to Almac’s headquarters …